As per a BSE filing, the Board also approved "issuance of unsecured/secured redeemable non-convertible debentures/bonds by way of private placement for an amount not exceeding Rs 12,500 crore".
The Board also cleared a proposal for issuance of equity shares including convertible bonds/debentures through qualified institutional placement (QIP) and or depository receipts or any other modes for an amount not exceeding Rs 5,000 crore, the company said in the filing.
The drug firm however did not mention what it intends to do with the proposed fundraising.
Disclaimer: No Business Standard Journalist was involved in creation of this content
